Diagnostic Imaging

Business

GE HealthCare Tops Revenue Forecasts in Q4 2025, Driven by Imaging and Diagnostics Demand

GE HealthCare Technologies posted stronger-than-expected fourth-quarter revenue of $5.70 billion, a 7.1% year-over-year increase, while adjusted earnings per share of $1.44 also edged past analyst consensus. The performance highlights steady demand for its medical imaging and pharmaceutical diagnostics units amid ongoing healthcare capital investment.

Feb 4, 2026

Business

Siemens Healthineers Navigates China Headwinds as Imaging and Therapy Units Drive Solid Q1

Siemens Healthineers reported a resilient start to fiscal 2026, with strong performance in its imaging and precision therapy divisions offsetting a significant downturn in its diagnostics business in China, prompting a strategic reassessment of its operations in the key Asian market.

Feb 5, 2026

Business

GE HealthCare Posts $20.6B in FY25 Revenue, Fueled by Sustained Demand for Imaging Technology

The medtech giant surpassed financial expectations, driven by robust performance in its core imaging and pharmaceutical diagnostics segments, while outlining a strategic shift towards becoming a comprehensive healthcare solutions provider.

Feb 4, 2026

Business

GE HealthCare Projects Strong 2026 Profit, Fueled by Sustained Demand for Medical Imaging

GE HealthCare Technologies Inc. has issued an upbeat profit forecast for 2026, surpassing analyst expectations, as hospitals continue to invest heavily in diagnostic and imaging equipment amid steady procedural volumes.

Feb 4, 2026

Business

IDEXX Charts New Course: CEO Succession Plan and AI-Powered Imaging System Unveiled

IDEXX Laboratories announces a planned CEO transition for 2026 alongside the launch of its flagship AI veterinary imaging platform, signaling a dual focus on leadership continuity and technological innovation in the competitive animal health diagnostics market.

Feb 2, 2026

Business

FDA Greenlights Spectrum Dynamics' AI-Powered Imaging Platform, Boosting Nuclear Medicine Precision

The FDA clearance of Spectrum Dynamics' Veritas.AI platform marks a significant step forward for nuclear imaging, promising to cut scan times in half and enhance image clarity for critical applications like cancer theranostics.

Jan 30, 2026

Business

AMETEK Acquires LKC Technologies, Bolstering Its Position in Ophthalmic Diagnostics

AMETEK expands its medical technology portfolio with the strategic acquisition of LKC Technologies, a specialist in eye diagnostics, as the company continues its targeted growth strategy in premium healthcare segments.

Feb 4, 2026

Business

Quest Diagnostics: A Value Play in Healthcare After Strong Run?

Shares of Quest Diagnostics (DGX) have delivered robust returns over multiple timeframes, prompting investors to question if the rally has room to run. A deep dive into valuation metrics suggests the stock may still be trading at a discount to its intrinsic value, even after recent gains.

Feb 4, 2026

Business

GE HealthCare's Allia Moveo Imaging System Clears FDA and CE Mark, Aims to Redefine Interventional Suite Flexibility

GE HealthCare secures dual US and European regulatory approvals for its new Allia Moveo imaging system, designed to enhance patient comfort and streamline clinical workflows in minimally invasive procedures.

Feb 3, 2026

Business

Molecular Partners' DLL3-Targeting Radiotherapeutic Shows Promising Imaging Data, U.S. Trial Set to Begin

New clinical imaging data for Molecular Partners' experimental radiotherapeutic MP0712, targeting the DLL3 protein in cancers like small cell lung cancer, show favorable tumor targeting and healthy organ clearance. The company confirms its U.S. Phase I/II trial is now open for patient screening.

Feb 2, 2026

Business

Abbott's $21B Exact Sciences Acquisition Pivots Focus to Cancer Diagnostics as Nutrition Unit Overhauled

Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.

Feb 2, 2026

Business

Revvity Beats 2025 Forecasts on Diagnostics Strength, Offers Cautious 2026 Outlook

Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.

Feb 2, 2026

Business

IDEXX Laboratories Posts Strong Q4 Growth, Unveils Ambitious 2026 Outlook on Diagnostic Innovation

IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.

Feb 2, 2026

Business

Revvity Beats Q4 Forecasts, Sets Bullish 2026 Targets on Diagnostics Strength

Revvity (NYSE: RVTY) surged past fourth-quarter expectations and issued an upbeat 2026 outlook, driven by robust demand in its diagnostics division. The medical equipment maker's performance highlights a sector-wide resilience despite ongoing softness in academic research funding.

Feb 2, 2026

Business

Sony's Gaming and Imaging Units Power 22% Profit Surge, Offsetting Film Division Slowdown

Strong performance from PlayStation and image sensor divisions drove Sony's quarterly operating profit to $3.28 billion, prompting an upward revision of its full-year forecast, even as its Pictures business faced a quieter release schedule.

Feb 5, 2026

GeneDx CEO on a Mission: Ending the 'Diagnostic Odyssey' for Rare Diseases

In an exclusive interview, GeneDx CEO Katherine Stueland details how rapid genomic testing is transforming pediatric care, slashing diagnosis times from years to days and building a data-driven bridge to future therapies.

Feb 2, 2026

Business

IDEXX Laboratories Posts Strong Q4 2025, Driven by Diagnostic Innovation and Global Expansion

IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.

Feb 2, 2026

Business

Astronics Unveils FaultFinder ETS, Aiming to Cut Aircraft Downtime with Automated Diagnostics

Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.

Feb 2, 2026

Business

Guggenheim Boosts Bruker Price Target to $58, Citing Strong Diagnostics Outlook

Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.

Jan 30, 2026

Business

GE HealthCare Beats Q4 Estimates on Strong Product Launches and Recurring Service Growth

GE HealthCare Technologies posted better-than-expected fourth-quarter results, driven by robust demand in pharmaceutical diagnostics and momentum from new product rollouts. The company's focus on expanding its service-based revenue streams is central to its growth outlook.

Feb 5, 2026